Overexpression of hypoxia-inducible factor 1 alpha impacts FoxP3 levels in mycosis fungoides - Cutaneous T-cell lymphoma: Clinical implications

International Journal of Cancer

Volumn 134, Issue 9, 2014, Pages 2136-2145

  Alcantara Hernandez M ^a,b   Torres Zarate C ^a   Perez Montesinos G ^c   Jurado Santacruz, F ^c   Dominguez Gomez M A ^c   Peniche Castellanos, A ^d   Ferat Osorio, E ^a   Neri, N ^e   Nambo, M J ^e   Alvarado Cabrero, I ^f   Moreno Lafont, M ^b   Huerta Yepez, S ^g   Bonifaz, L C ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c CENTRO DERMATOLÓGICO DR LADISLAO DE LA PASCUA   (Mexico)

^d HOSPITAL GENERAL DE MÉXICO   (Mexico)

^e HOSPITAL DE ONCOLOGÍA   (Mexico)

^f Hospital de Oncologí   (Mexico)

^g HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

cutaneous T cell lymphoma; FoxP3; hypoxia inducible factor 1 alpha; mycosis fungoides

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CANCER PROGNOSIS; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CUTANEOUS T CELL LYMPHOMA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EX VIVO STUDY; GENE; GENE OVEREXPRESSION; GLYCOLYSIS; HIF 1 ALPHA GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SKIN DEFECT;

CUTANEOUS T-CELL LYMPHOMA; FOXP3; HYPOXIA INDUCIBLE FACTOR 1 ALPHA; MYCOSIS FUNGOIDES;

DISEASE PROGRESSION; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LYMPHOMA, T-CELL, CUTANEOUS; MYCOSIS FUNGOIDES; PROGNOSIS; SKIN NEOPLASMS; UP-REGULATION;

EID: 84896732610     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28546     Document Type: Article

References (46)

1. Girardi M, Heald PW, Wilson LD,. The pathogenesis of mycosis fungoides. N Engl J Med 2004; 350: 1978-88.
2. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53: 1053-63.
3. Robson A,. Immunocytochemistry and the diagnosis of cutaneous lymphoma. Histopathology 2010; 56: 71-90.
4. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014-30.
5. Karenko L, Hyytinen E, Sarna S, et al. Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods. J Invest Dermatol 1997; 108: 22-9.
6. Shapiro PE, Warburton D, Berger CL, et al. Clonal chromosomal abnormalities in cutaneous T-cell lymphoma. Cancer Genet Cytogenet 1987; 28: 267-76.
7. Alessi E, Coggi A, Venegoni L, et al. The usefulness of clonality for the detection of cases clinically and/or histopathologically not recognized as cutaneous T-cell lymphoma. Br J Dermatol 2005; 153: 368-71.
8. Girardi M, Heald PW, Wilson LD,. The pathogenesis of mycosis fungoides. N Engl J Med 2004; 350: 1978-88.
9. Burg G, Dummer R, Haeffner A, et al. From inflammation to neoplasia: mycosis fungoides evolves from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumors. Arch Dermatol 2001; 137: 949-52.
10. Jokinen CH, Fromm JR, Argenyi ZB, et al. Flow cytometric evaluation of skin biopsies for mycosis fungoides. Am J Dermatopathol 2011; 33: 483-91.
11. van Dongen JJM, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908-75.
12. Michie SA, Abel EA, Hoppe RT, et al. Discordant expression of antigens between intraepidermal and intradermal T cells in mycosis fungoides. Am J Pathol 1990; 137: 1447-51.
13. Saed G, Fivenson DP, Naidu Y, et al. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile. J Invest Dermatol 1994; 103: 29-33.
14. Cirée A, Michel L, Camilleri-Bröet S, et al. Expression and activity of IL-17 in cutaneous T-cell lymphomas(mycosis fungoides and sezary syndrome). Int J Cancer 2004; 112: 113-20.
15. Sigurdsson V, Toonstra J, Bihari IC, et al. Interleukin 4 and interferon-gamma expression of the dermal infiltrate in patients with erythroderma and mycosis fungoides. An immuno-histochemical study. J Cutan Pathol 2000; 27: 429-35.
16. Miyagaki T, Sugaya M, Suga H, et al. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res 2011; 17: 7529-38.
17. Krejsgaard TOR, Ralfkiaer U, Clasen-Linde E, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol 2011; 131: 1331-8.
18. Tiemessen MM, Mitchell TJ, Hendry L, et al. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126: 2217-23.
19. Klemke CD, Fritzsching B, Franz B, et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20: 1123-9.
20. Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007; 21: 2512-8.
21. Solomon GJ, Magro CM,. Foxp3 expression in cutaneous T-cell lymphocytic infiltrates. J Cutan Pathol 2008; 35: 1032-9.
22. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490-500.
23. Clambey ET, McNamee EN, Westrich JA, et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci USA 2012; 109: E2784-93.
24. Dang EV, Barbi J, Yang H-Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011; 146: 772-84.
25. Semenza GL,. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001; 13: 167-71.
26. Semenza GL,. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
27. Shi LZ, Wang R, Huang G, et al. HIF1-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med 2011; 208: 1367-76.
28. Linehan WM, Bratslavsky G, Pinto PA, et al. Molecular Diagnosis and Therapy of Kidney Cancer. Annu Rev Med 2010; 61: 329-43.
29. Dales J-P, Beaufils N, Silvy M, et al. Hypoxia inducible factor 1alpha gene (HIF-1alpha) splice variants: potential prognostic biomarkers in breast cancer. BMC Med 2010; 8: 44.
30. Rasheed S, Harris AL, Tekkis PP, et al. Hypoxia-inducible factor-1α and -2α are expressed in most rectal cancers but only hypoxia-inducible factor-1α is associated with prognosis. 2009; 100: 1666-73.
31. Wang Y, Liu Y, Malek SN, et al. Targeting HIF1α Eliminates Cancer Stem Cells in Hematological Malignancies. Stem Cell 2011; 8: 399-411.
32. Maynard MA, Ohh M,. The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 2007; 64: 2170-80.
33. Larbi A, Zelba H, Goldeck D, et al. Induction of HIF-1alpha and the glycolytic pathway alters apoptotic and differentiation profiles of activated human T cells. J Leukoc Biol 2010; 87: 265-73.
34. Passam FH, Alexandrakis MG, Kafousi M, et al. Histological expression of angiogenic factors: VEGF, PDGFRα, and HIF-1α in Hodgkin lymphoma. Pathol Res Pract 2009; 205: 11-20.
35. Nickoloff BJ, Griffiths CE,. Intraepidermal but not dermal T lymphocytes are positive for a cell-cycle-associated antigen (Ki-67) in mycosis fungoides. Am J Pathol 1990; 136: 261-6.
36. Arun I, Wulu JA, Janik JE, et al. Visual inspection versus quantitative flow cytometry to detect aberrant CD2 expression in malignant T cells. Cytometry 2009; 9999B:NA-NA.
37. Yuan Y,. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem 2003; 278: 15911-6.
38. Li B, Takeda K, Yokoyama S, et al. A Prolyl-hydroxylase Inhibitor, Ethyl-3,4-dihydroxybenzoate, Induces Haem Oxygenase-1 Expression in Human Cells Through a Mechanism Independent of Hypoxia-inducible Factor-1. J Biochem 2008; 144: 643-54.
39. Smoller BR,. Mycosis fungoides: what do/do not we know? J Cutan Pathol 2008; 35: 35-9.
40. Calzada MJ, Peso L,. Hypoxia-inducible factors and cancer. Clin Transl Oncol 2007; 9: 278-89.
41. Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 2013; 496: 238-42.
42. Ben-Shoshan J, Maysel-Auslender S, Mor A, et al. Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol 2008; 38: 2412-8.
43. Rezvani HR, Ali N, Nissen LJ, Harfouche G, de Verneuil H, Taïeb A, Mazurier F,. HIF-1α in epidermis: oxygen sensing, cutaneous angiogenesis, cancer, and non-cancer disorders. J Invest Dermatol 2011; 131: 1793-805.
44. Al Okail MS,. Cobalt chloride, a chemical inducer of hypoxia-inducible factor-1α in U251 human glioblastoma cell line. J Saudi Chem Soc 2010; 14: 197-201.
45. Bagot M, Nikolova M, Schirm-Chabanette F, et al. Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas. Ann NY Acad Sci 2001; 941: 31-8.
46. Alaibac M, Pigozzi B, Belloni-Fortina A, et al. CD7 expression in reactive and malignant human skin T-lymphocytes. Anticancer Res 2003; 23: 2707-10.